Trial Profile
An Open Label, Single-Arm, Phase 1b/2 Study of the Safety and Efficacy of Combination Treatment With Lenalidomide, Bortezomib, Dexamethasone and Siltuximab (CNTO 328) in Subjects With Newly Diagnosed, Previously Untreated Multiple Myeloma Requiring Systemic Chemotherapy
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 26 Jun 2015
Price :
$35
*
At a glance
- Drugs Siltuximab (Primary) ; Bortezomib; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 13 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 12 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center record.
- 08 Dec 2012 Status changed from active, no longer recruiting to recruiting as reported by M.D. Anderson Cancer Center record.